BR112022002107A2 - Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo - Google Patents

Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo

Info

Publication number
BR112022002107A2
BR112022002107A2 BR112022002107A BR112022002107A BR112022002107A2 BR 112022002107 A2 BR112022002107 A2 BR 112022002107A2 BR 112022002107 A BR112022002107 A BR 112022002107A BR 112022002107 A BR112022002107 A BR 112022002107A BR 112022002107 A2 BR112022002107 A2 BR 112022002107A2
Authority
BR
Brazil
Prior art keywords
same
preparation
application
vmat2
vmat2 inhibitor
Prior art date
Application number
BR112022002107A
Other languages
English (en)
Inventor
Bo Cui
Dawei Yu
Fangxia Zou
Guangying Du
Jingwei Tian
Liang Ye
Rui Zhang
Zongliang Liu
Original Assignee
Shandong luye pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong luye pharmaceutical co ltd filed Critical Shandong luye pharmaceutical co ltd
Publication of BR112022002107A2 publication Critical patent/BR112022002107A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

inibidor de vmat2 e método de preparação para o mesmo e aplicação do. a presente invenção refere-se a uma classe de compostos que serve como inibidores de vmat2 e se refere, em particular, a um composto representado pela fórmula (i), ou um estereoisômero ou sal farmaceuticamente aceitável do mesmo, e um método de preparação para o mesmo, assim como a aplicação do mesmo na preparação de um medicamento para tratar doenças relacionadas ao vmat2.
BR112022002107A 2019-08-12 2020-08-11 Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo BR112022002107A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910739845 2019-08-12
CN201911094084 2019-11-11
PCT/CN2020/108314 WO2021027792A1 (zh) 2019-08-12 2020-08-11 Vmat2抑制剂及其制备方法和应用

Publications (1)

Publication Number Publication Date
BR112022002107A2 true BR112022002107A2 (pt) 2022-04-12

Family

ID=74570226

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002107A BR112022002107A2 (pt) 2019-08-12 2020-08-11 Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo

Country Status (9)

Country Link
US (1) US20220340562A1 (pt)
EP (1) EP4015517A4 (pt)
JP (1) JP2022547390A (pt)
KR (1) KR20220035204A (pt)
CN (2) CN115260186A (pt)
AU (1) AU2020327501A1 (pt)
BR (1) BR112022002107A2 (pt)
CA (1) CA3148302A1 (pt)
WO (1) WO2021027792A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022203984A1 (en) * 2021-03-22 2022-09-29 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use
WO2024064178A1 (en) * 2022-09-21 2024-03-28 Neurocrine Biosciences, Inc. Hexahydro-2h-pyrido[2,1-a]isoquinoline vmat2 inhibitors and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101429302B1 (ko) * 2006-05-02 2014-08-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 방사성 표지된 디히드로테트라베나진 유도체 및 조영제로서의 이의 용도
CA2668689C (en) * 2006-11-08 2015-12-29 Neurocrine Biosciences Inc. Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
US7897768B2 (en) * 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CN102120742B (zh) * 2010-01-08 2013-03-13 中国药科大学 一种丁苯那嗪的制备方法
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
TW201906818A (zh) * 2017-05-31 2019-02-16 美商５１１製藥公司 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
SG11202004165UA (en) * 2017-11-08 2020-06-29 Yuhua Li Esters of dihydrotetrabenazine
CA3086611C (en) * 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof

Also Published As

Publication number Publication date
US20220340562A1 (en) 2022-10-27
CN114302883B (zh) 2022-09-06
EP4015517A4 (en) 2023-10-18
CN115260186A (zh) 2022-11-01
CN114302883A (zh) 2022-04-08
AU2020327501A1 (en) 2022-02-24
JP2022547390A (ja) 2022-11-14
WO2021027792A1 (zh) 2021-02-18
CA3148302A1 (en) 2021-02-18
KR20220035204A (ko) 2022-03-21
EP4015517A1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
CL2019002204A1 (es) Compuestos inhibidores del vih.
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
BR112022010383A2 (pt) Compostos tricíclicos substituídos
UY38057A (es) Inhibidores de sarcómero cardíaco
DOP2021000077A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BRPI1014802B8 (pt) profármacos de triptolida.
BR112018074027A2 (pt) tiofeno, método de fabricação do mesmo, e aplicação farmacêutica do mesmo
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
UY37941A (es) Derivados de bencimidazol y sus usos
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
CO2021014210A2 (es) Compuestos de pirrol
UY38618A (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GENEORA PHARMA (SHIJIAZHUANG) CO., LTD. (CN)